Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Long-Term Debt Repayments (2016 - 2018)

Historic Long-Term Debt Repayments for Cardiff Oncology (CRDF) over the last 3 years, with Q2 2018 value amounting to $1.0 million.

  • Cardiff Oncology's Long-Term Debt Repayments fell 9296.99% to $1.0 million in Q2 2018 from the same period last year, while for Mar 2019 it was $1.0 million, marking a year-over-year decrease of 9304.33%. This contributed to the annual value of $1.2 million for FY2018, which is 9199.98% down from last year.
  • According to the latest figures from Q2 2018, Cardiff Oncology's Long-Term Debt Repayments is $1.0 million, which was down 9296.99% from $156526.0 recorded in Q1 2018.
  • Cardiff Oncology's 5-year Long-Term Debt Repayments high stood at $14.8 million for Q2 2017, and its period low was $156526.0 during Q1 2017.
  • Its 3-year average for Long-Term Debt Repayments is $3.6 million, with a median of $1.0 million in 2018.
  • Its Long-Term Debt Repayments has fluctuated over the past 5 years, first soared by 96008.23% in 2017, then tumbled by 9296.99% in 2018.
  • Quarter analysis of 3 years shows Cardiff Oncology's Long-Term Debt Repayments stood at $6.6 million in 2016, then skyrocketed by 125.72% to $14.8 million in 2017, then tumbled by 92.97% to $1.0 million in 2018.
  • Its Long-Term Debt Repayments stands at $1.0 million for Q2 2018, versus $156526.0 for Q1 2018 and $14.8 million for Q2 2017.